Concurrent with the public offering, Alder intends to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), up to
Alder intends to use the net proceeds from the public offering and the concurrent private placement, together with other available funds, for the commercialization of eptinezumab up to and through launch and the manufacture of commercial supply for eptinezumab, and may also use net proceeds for future eptinezumab clinical trials, the development of ALD1910 and for working capital and general corporate purposes.
A shelf registration statement relating to the public offering was filed with the
The shares of common stock to be sold in the concurrent private placement have not been registered under the Securities Act or under any state securities laws and, unless so registered may not be offered or sold in
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Alder’s expectations regarding the completion, timing and size of the public offering and concurrent private placement, its expectations with respect to granting the underwriters a 30-day option to purchase additional shares, its anticipated use of net proceeds from the public offering and concurrent private placement, and the continued development of eptinezumab, and establishment of the commercial drug supply chain. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering or the concurrent private placement on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering or the concurrent private placement. More information about the risks and uncertainties faced by Alder will be included in the section captioned “Risk Factors” in the preliminary prospectus supplement related to the public offering to be filed with
|Investor Relations Contact:
Stern Investor Relations, Inc.
Source: Alder BioPharmaceuticals, Inc.